share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  04/17 16:37
Moomoo AI 已提取核心信息
On April 17, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, held a special meeting of stockholders to vote on several key proposals. The meeting saw a quorum with proxies representing approximately 39% of the outstanding shares. The primary agenda was the approval of a Charter Amendment for a Reverse Stock Split, which was adopted with 2,058,182 votes in favor and 899,831 against. The approved amendment allows the board of directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50, at their discretion, without further stockholder approval. Additionally, a proposal to adjourn the meeting to solicit more proxies was approved, but rendered moot as the Reverse Stock Split received sufficient votes. The board has set the reverse stock split ratio at 1-for-10, to take effect at 4:01 p.m. Eastern Time on April 25, 2024. ZyVersa Therapeutics' common stock will trade on a post-split basis on The Nasdaq Capital Market starting April 26, 2024, under a new CUSIP number 98987D 300.
On April 17, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, held a special meeting of stockholders to vote on several key proposals. The meeting saw a quorum with proxies representing approximately 39% of the outstanding shares. The primary agenda was the approval of a Charter Amendment for a Reverse Stock Split, which was adopted with 2,058,182 votes in favor and 899,831 against. The approved amendment allows the board of directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50, at their discretion, without further stockholder approval. Additionally, a proposal to adjourn the meeting to solicit more proxies was approved, but rendered moot as the Reverse Stock Split received sufficient votes. The board has set the reverse stock split ratio at 1-for-10, to take effect at 4:01 p.m. Eastern Time on April 25, 2024. ZyVersa Therapeutics' common stock will trade on a post-split basis on The Nasdaq Capital Market starting April 26, 2024, under a new CUSIP number 98987D 300.
2024年4月17日，生物制药公司ZyVersa Therapeutics, Inc. 举行了一次股东特别会议，对几项关键提案进行投票。会议达到了法定人数，代理人约占已发行股份的39％。主要议程是批准反向股票分割的章程修正案，该修正案以2,058,182票赞成，899,831票反对获得通过。经批准的修正案允许董事会自行决定以1比2和1比50的比例进行反向股票分割，而无需进一步获得股东的批准。此外，一项关于休会以征集更多代理人的提议获得批准，但由于反向股票拆分获得了足够的选票，因此没有实际意义。董事会已将反向股票拆分比率设定为1比10，将于美国东部时间2024年4月25日下午 4:01 生效。自2024年4月26日起，ZyVersa Therapeutics的普通股将在拆分后在纳斯达克资本市场上市，新的CUSIP编号为98987D 300。
2024年4月17日，生物制药公司ZyVersa Therapeutics, Inc. 举行了一次股东特别会议，对几项关键提案进行投票。会议达到了法定人数，代理人约占已发行股份的39％。主要议程是批准反向股票分割的章程修正案，该修正案以2,058,182票赞成，899,831票反对获得通过。经批准的修正案允许董事会自行决定以1比2和1比50的比例进行反向股票分割，而无需进一步获得股东的批准。此外，一项关于休会以征集更多代理人的提议获得批准，但由于反向股票拆分获得了足够的选票，因此没有实际意义。董事会已将反向股票拆分比率设定为1比10，将于美国东部时间2024年4月25日下午 4:01 生效。自2024年4月26日起，ZyVersa Therapeutics的普通股将在拆分后在纳斯达克资本市场上市，新的CUSIP编号为98987D 300。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息